Is it time to conclude that NMDA antagonists have failed?
Roesler
Rafael
R
GENOTOX Laboratory, Center for Biotechnology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. genotox@dna.cbiot.ufrgs.br <genotox@dna.cbiot.ufrgs.br>
Quevedo
João
J
Schröder
Nadja
N
D000818:Animals; D001930:Brain Injuries / Q000188:drug therapy; D002986:Clinical Trials as Topic; D018691:Excitatory Amino Acid Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D020521:Stroke / Q000188:drug therapy
D018691:Excitatory Amino Acid Antagonists; D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate